Akebia Therapeutics
$0.8484
127
-$0.01-1.35% 15:20 Today
Statistics
Day High
0.8626
Day Low
0.8382
52W High
3.29
52W Low
0.844
Volume
526,118
Avg. Volume
5,169,327
Mkt Cap
235.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.1
-0.06
-0.01
0.03
Expected EPS
-0.04
Actual EPS
N/A
Financials
-2.26%Profit Margin
Unprofitable236.2MRevenue
-5.35MNet Income
Analyst Ratings
5.00Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AKBA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap242.64B
GSK
GSK
Mkt Cap99.18B
AMGEN
AMGN
Mkt Cap224.63B
Johnson & Johnson
JNJ
Mkt Cap627.42B
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
About
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Show more...
CEO
John Butler
Employees
194
Country
United States
ISIN
US00972D1054
WKN
000A1XF0S
Listings
0 Comments
Share your thoughts
FAQ
What is Akebia Therapeutics stock price today?▼
The current price of AKBA is $0.85 USD — it has decreased by -1.35% in the past 24 hours. Watch Akebia Therapeutics stock price performance more closely on the chart.
What is Akebia Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Akebia Therapeutics stocks are traded under the ticker AKBA.
Is Akebia Therapeutics stock price growing?▼
AKBA stock has fallen by -2.03% compared to the previous week, the month change is a -36.65% fall, over the last year Akebia Therapeutics has showed a -72.7% decrease.
What is Akebia Therapeutics market cap?▼
Today Akebia Therapeutics has the market capitalization of 235.1M
When is the next Akebia Therapeutics earnings date?▼
Akebia Therapeutics is going to release the next earnings report on October 29, 2026.
What were Akebia Therapeutics earnings last quarter?▼
AKBA earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.04 USD resulting in a +28.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Akebia Therapeutics revenue for the last year?▼
Akebia Therapeutics revenue for the last year amounts to 236.2M USD.
What is Akebia Therapeutics net income for the last year?▼
AKBA net income for the last year is -5.35M USD.
How many employees does Akebia Therapeutics have?▼
As of August 18, 2026, the company has 194 employees.
In which sector is Akebia Therapeutics located?▼
Akebia Therapeutics operates in the Health & Wellness sector.
When did Akebia Therapeutics complete a stock split?▼
Akebia Therapeutics has not had any recent stock splits.
Where is Akebia Therapeutics headquartered?▼
Akebia Therapeutics is headquartered in CAMBRIDGE, United States.